AIP
VIGL

Ameritas Investment Partners’s Vigil Neuroscience VIGL Stock Holding History

Ameritas Investment Partners’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,327
Closed -$4.53K – 3236
2024
Q1 		$4.53K Hold
1,327
– – ﹤0.01% 2964
2023
Q4 		$4.49K Hold
1,327
– – ﹤0.01% 2986
2023
Q3 		$7.15K Hold
1,327
– – ﹤0.01% 2922
2023
Q2 		$12.5K Buy
+1,327
New +$12.5K ﹤0.01% 2822
2022
Q2 		– Sell
-500
Closed -$4K – 3242
2022
Q1 		$4K Buy
+500
New +$6.6K ﹤0.01% 3010

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Ameritas Investment Partners's VIGL Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Vigil Neuroscience (VIGL) in Q2 2024, closing a stake of 1,327 shares — an estimated $4.53K sold.

Ameritas Investment Partners first reported a position in VIGL in Q1 2022 and held it in 5 quarters. The position peaked at $12.5K in Q2 2023. 58 funds tracked by Wall St. Rank hold VIGL as of Q2 2024.

  • Ameritas Investment Partners reported no remaining Vigil Neuroscience position as of Q2 2024 after selling out during the quarter.
  • Ameritas Investment Partners sold 1,327 Vigil Neuroscience shares in Q2 2024, an estimated $4.53K.
  • Ameritas Investment Partners first reported a position in Vigil Neuroscience in Q1 2022 and held it in 5 quarters.
  • Ameritas Investment Partners's Vigil Neuroscience position peaked at $12.5K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.